Note 11. Subsequent Events

On March 30, 2026, MSI BVF SPV, LLC provided us notice of its intention to exercise 87,300 pre-funded warrants for 87,269 shares of the Company’s common stock pursuant to a cashless exercise provision. The common shares were issued on April 10, 2026, pursuant to the terms of an underwriting agreement, dated October 29, 2024, by and between the Company and Leerink Partners, LLC, as representative of the several underwriters named therein and did not result in the receipt of cash proceeds by the Company.

On March 30, 2026, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC provided us notice of its intention to convert an aggregate of 22,479 shares of the Company’s Series X1 Convertible Preferred Stock for an aggregate of 1,248,832 shares of the Company’s common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X1 Non-Voting Convertible Preferred Stock. The conversion was completed on April 9, 2026, and did not result in the receipt of cash proceeds by the Company.